Literature DB >> 10653004

Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.

H Fujisawa1, R M Reis, M Nakamura, S Colella, Y Yonekawa, P Kleihues, H Ohgaki.   

Abstract

Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways. Primary glioblastomas are characterized by EGFR and MDM2 amplification/overexpression, PTEN mutations, and p16 deletions, whereas secondary glioblastomas frequently contain p53 mutations. Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested. We carried out deletion mappings on chromosome 10, using PCR-based microsatellite analysis. LOH#10 was detected at similar frequencies in primary (8/17; 47%) and secondary glioblastomas (7/13; 54%). The majority (88%) of primary glioblastomas with LOH#10 showed LOH at all informative markers, suggesting loss of the entire chromosome 10. In contrast, secondary glioblastomas with LOH#10 showed partial or complete loss of chromosome 10q but no loss of 10p. These results are in accordance with the view that LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic end point of both genetic pathways, whereas LOH on 10p is largely restricted to the primary (de novo) glioblastoma.

Entities:  

Mesh:

Year:  2000        PMID: 10653004     DOI: 10.1038/labinvest.3780009

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  47 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Assessing the cytoskeletal system and its elements in C6 glioma cells and astrocytes by atomic force microscopy.

Authors:  Dexiang Zhou; Xiaodan Jiang; Ruxiang Xu; Yingqian Cai; Jiliang Hu; Gang Xu; Yuxi Zou; Yanjun Zeng
Journal:  Cell Mol Neurobiol       Date:  2008-03-04       Impact factor: 5.046

3.  MRI findings and pathological features in early-stage glioblastoma.

Authors:  Makoto Ideguchi; Koji Kajiwara; Hisaharu Goto; Kazutaka Sugimoto; Sadahiro Nomura; Eiji Ikeda; Michiyasu Suzuki
Journal:  J Neurooncol       Date:  2015-05-05       Impact factor: 4.130

4.  Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review).

Authors:  Xiang Zhang; Wei Zhang; Wei-Dong Cao; Gang Cheng; Yong-Qiang Zhang
Journal:  Exp Ther Med       Date:  2011-10-18       Impact factor: 2.447

5.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.

Authors:  Jean-François Mineo; Anne Bordron; Marc Baroncini; Claude-Alain Maurage; Carole Ramirez; Rose-Mary Siminski; Christian Berthou; Phong Dam Hieu
Journal:  J Neurooncol       Date:  2007-06-15       Impact factor: 4.130

Review 6.  Pathology and molecular genetics of astrocytic gliomas.

Authors:  Guido Reifenberger; Vincent Peter Collins
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

Review 7.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

8.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.

Authors:  Renate Kessler; Franziska Bleichert; Jan-Peter Warnke; Klaus Eschrich
Journal:  J Neurooncol       Date:  2007-09-06       Impact factor: 4.130

9.  Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Authors:  Rodney N Wiltshire; James E Herndon; Annie Lloyd; Henry S Friedman; Darell D Bigner; Sandra H Bigner; Roger E McLendon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

10.  Glioblastoma Multiforme Oncogenomics and Signaling Pathways.

Authors:  Okezie O Kanu; Betsy Hughes; Chunhui Di; Ningjing Lin; Jinrong Fu; Darell D Bigner; Hai Yan; Cory Adamson
Journal:  Clin Med Oncol       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.